-
Portrait | 2024.03.05
Carla Saleh, leading the fight against viruses and inequality
When Carla Saleh arrived in France from Argentina aged 25 as a young scientist, she didn't speak a word of French. She now leads her own research unit at the Institut Pasteur.Her goal is to make mosquitoes intolerant to viruses. She is passionate about science, determined to tackle all forms of inequality and discrimination, and always keen to encourage anyone – especially girls and women – with...
-
Report | 2024.03.12
COVID-19: which monoclonal antibodies should be used for vulnerable individuals?
Vaccination does not offer sufficient protection against severe forms of COVID-19 for people with a weakened immune system. For these individuals, monoclonal antibodies have long been the preferred therapeutic solution. But depending on the SARS-CoV-2 variant, the effectiveness of these treatments has fluctuated. Scientists have had to develop novel antibodies that are more effective while also...
-
Article | 2024.03.12
DIAGNOSTIC
DiagnosticFrançois Rieunier, Head of Diagnostic Innovation DevelopmentFrançois Rieunier joined the Technology Transfer and Industrial Partnership Department in 2023 as Head of Dianostic Innovation Development.After a PhD from the University of Montpellier, in Chemistry applied to Biology, François joined the Biological Development team at Sanofi Diagnostic Pasteur in Marnes la Coquette...
-
Article | 2024.03.12
VACCINE
VaccineDr. Sotiris MissailidisHead of Vaccine Innovation DevelopmentSotiris is managing the vaccine portfolio of the Institute Pasteur and leading the Innovation development of vaccine projects from basic research to clinical development, spin-off activities and industrial partnerships for vaccine-related projects. Sotiris joined the Institute Pasteur in 2024, having previously led for...
-
Article | 2024.03.14
Transaction & Partnership
The Transaction & Partnership Team is focused on the preparation, the drafting and the negotiation of contracts with our partners such as non-disclosure agreements, material transfer agreements, licensing agreements, collaborative research agreements and fee for service agreements.
-
Article | 2024.03.14
Startup
The Startup team coordinates the process of creating startups based on Pasteur's discoveries. The team supports scientists at various stages of this process: raising awareness and providing training in entrepreneurship, identifying business creation potential, providing advice, and finding financial and industrial partners. Thanks to its integration in the innovation ecosystem, the Startup team...
-
News | 2024.03.19
Pasteur Museum: transferring the collections to protect them
As part of the work to restore and renovate the Institut Pasteur's historical building, the Pasteur Museum recently embarked on an unprecedented process to transfer its collections. This involves meticulously preparing the items so that they can be stored in dedicated spaces that are suitable for housing such valuable objects.
-
News | 2024.03.25
Tackling flaviviruses and preparing the European Union for emerging threats
The genus flavivirus includes several human pathogens, such as Zika, dengue, West Nile virus (WNV) and yellow fever virus, which persist as major threats to global public health. Yellow4FLAVI, coordinated by Giovanna Barba-Spaeth, Institut Pasteur, comprises 13 partner institutions and is supported by the European Union with with € 8 million. The aim is to use the 17D yellow fever vaccine as...
-
Document de presse | 2024.03.28
Inauguration in Brazil of the Institut Pasteur de São Paulo, member of the Pasteur Network
On March 27, 2024, the Institut Pasteur de São Paulo was inaugurated by French President, Emmanuel Macron. As a member of the Pasteur Network, this institute, founded by the Institut Pasteur and the University of São Paulo, conducts international-level research in the field of health biology to further understanding of diseases and their impact on human health, especially in the context of...
-
News | 2024.03.27
Cancer: unexpected mechanism of action of immunotherapy revealed
Immunotherapy, now in widespread use as a treatment for cancer, continues to be a focus of research and to teach us more about the immune system. A new study by scientists at the Institut Pasteur has identified a novel mechanism of action of anti-PD-1 antibodies, a commonly used form of immunotherapy.
